{
  "id": "cluster_2_doc4",
  "content": "Claims audit CX4782 shows $14,220 in outstanding costs for repeated ER visits (03/2023-10/2023) related to pancreatic flare-ups. Authorization for definitive treatment approved 11/20/2023 after two appeals. Case flagged for quality review due to extended pre-treatment complication period.",
  "metadata": {
    "format": "audit_report"
  }
}